Open, non-randomized phase II pilot study of neoadjuvant cetuximab in combination with cisplatin and gemcitabine, to evaluate their efficacy, safety and biological pharmacodynamic effects in patients with resectable stage IB-IIIA non small cell lung cancer (NSCLC).

Trial Profile

Open, non-randomized phase II pilot study of neoadjuvant cetuximab in combination with cisplatin and gemcitabine, to evaluate their efficacy, safety and biological pharmacodynamic effects in patients with resectable stage IB-IIIA non small cell lung cancer (NSCLC).

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2011

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 11 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top